Non-alcoholic Steatohepatitis Treatment Market Trends

Growth Drivers

• Rising Cases of Obesity– NASH tend to develop in the people who are overweight or at a risk of obesity. As per the data of the World Health Organization, around the world, 650 million adults, 340 million teenagers, and 39 million children are obese. Moreover, this count is expected to continuously rise owing to the unhealthy lifestyle of people. It is anticipated that by 2025, there are likely be 167 million adults and children living with obesity.
• Growing Burden of Liver Disease With a 25% global prevalence, nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease. In addition to liver fat, NASH is a variant of NAFLD in which the liver is also inflamed and damaged.
• Growing Success of Medication Developed for NASH- For instance, Madrigal Pharmaceuticals developed a drug, Resmetirom for NASH. In its trial, around 26% of individuals who received the medication in an 80 mg dose had their NASH resolved.

Challenges

• Difficulty faced during the formulation of the drugs- The development of drugs for the treatment of NASH can be tedious since liver fibrosis develops slowly and gradually over many years or decades. The level of benefit from a patient's lifetime treatment for NASH must be weighed against the drug's safety profile. As NASH patients are also susceptible to other illnesses, the drug treatment should be developed while keeping in mind the other issues including cardiovascular disease, hyperlipidemia, metabolic disease, and diabetes.
• Patients with NASH are susceptible to abnormalities
• Large size of population with NASH is still under-diagnosed